Gnosis Spa

Dow Silicones Corporation

Lesaffre Et Compagnie

Davide Bianchi

Marco Valetti

Paola Bazza

Ermanno Valoti

Niccolo Miraglia

Frederic Gubbels

Tatiana Dimitrova

Victor Baily

Simona Daly

Niccolò Miraglia

Nicola Angelo Maria Volpi

Federica Colzani

Antonella Trentin

Auro Roberto Tagliani

Francesca Bollini

Cesare Ponzone

Nicolò Miraglia

Mauro Rossini

Immacolata Busiello

Marco Agostinetto

Antonio Trilli

The invention relates to a novel process for obtaining direct sulfation of unprotected sugars, in particular polysaccharides, using ecologically acceptable solvents.

Process for direct sulfation of polysaccharides in an ecologically acceptable solvent

Improvements in or relating to transparent units (such as glazing units, which may also be referred to as insulating glass units) and their methods of manufacture are disclosed. Each transparent unit comprises first and second panes of transparent material each having an outwardly facing side and an inwardly facing side. Each inwardly facing side is at least partially coated with a reactive interlayer made by the application of a reactive interlayer coating composition. The inwardly facing side of the first and second panes of transparent material are spaced apart partially or totally by a transparent spacer made of a pre-cured condensation curable material or a substantially pre-cured condensation curable material adhered to the inwardly facing side of the first and second panes of transparent material by way of the reactive interlayers. In various embodiments, the pre-cured condensation curable material is a silicone based material.

Transparent unit

Disclosed is a low molecular weight (1000-5000 daltons) chondroitin sulfate (CS) produced by chemical sulfation of a non-sulfated chondroitin backbone (K4 capsular polysaccharide) obtained with biotechnology techniques. The CS described is substantially monosulfated, mainly at the 6-position, with very little sulfation at the 4-position, and with a mono/disulfated disaccharide ratio and charge density similar to those of natural CS. Said biotechnological chondroitin sulfate (CS) is useful in the treatment and prevention of osteoarthritis and in acute and chronic inflammatory processes.

Low polydispersity, low molecular weight biotechnological chondroitin sulfate with anti-inflammatory and antiarthritis activity and use thereof in the prevention of osteoarthritis

Disclosed are solid forms of menaquinol and processes for obtaining them by chemical or enzymatic reduction of menaquinone. Said solid forms possess high stability to oxidation which allows effective use of menaquinol in the most common formulations wherein vitamin K2 is used.

Solid forms of menaquinols

The present invention discloses a process for the production of chondroitin sulphate with an average molecular weight (Mw) of 10-30 kDa by chemical sulphation starting from an unsulphated chondroitin backbone, obtained in turn by acid hydrolysis of capsular polysaccharide K4 made directly fromstrain O5:K4:H4, or directly produced from a genetically modified strain of. Sulphation of the N-acetyl-D-galactosamine residue at position 4 or 6 takes place simultaneously in the same polysaccharide chain, simulating the sulphation pattern observed in natural chondroitin sulphate, unlike the sulphation obtained with the synthesis methods described to date.

Biotechnological sulphated chondroitin sulphate at position 4 or 6 on the same polysaccharide chain, and process for the preparation thereof

Disclosed are two novel crystalline forms of S-acetyl glutathione (SAG) called Form A and Form B, obtained by crystallization of SAG from mixtures of water-acetone, water-ethanol or water acetone under controlled conditions. Forms A and B can be advantageously used as ingredients of pharmaceutical or nutraceutical formulations.

Crystalline forms of s-acetyl glutathione, their preparations and uses in pharmaceutical and nutraceutical formulations

A process for the preparation of a chondroitin sulphate salt with an average molecular weight (Mw) of 10-30 kDa via chemical sulphation of an unsulphated chondroitin backbone is provided. The unsulphated chondroitin can be obtained by acid hydrolysis of a capsular polysaccharide K4 made directly fromstrain O5:K4:H4 or directly produced from a genetically modified strain of. Sulphation of the N-acetyl-D-galactosamine residue at position 4 or 6 takes place simultaneously in the same polysaccharide chain, simulating the sulphation pattern observed in natural chondroitin sulphate.

The present invention provides a shark-like chondroitin sulphate and a process for the preparation thereof. In particular, the present invention relates to a shark-like chondroitin sulphate, having a very low amount of 4-sulphate, a high charge density and a biological activity comparable to natural chondroitin sulphates. The invention also relates to a process for the preparation of said shark-like chondroitin sulphate affording substantially higher productivities and better reproducibility of product quality. The shark-like chondroitin sulphate of the invention shows a high molecular mass and its in vitro biological and anti-inflammatory effectiveness has been shown to be comparable to that of natural products making this polysaccharide potentially useful as a drug in pharmaceutical preparations and nutraceuticals.

Shark-like chondroitin sulphate and process for the preparation thereof

The present invention relates to folates, compositions and uses thereof; In particular, this invention describes a crystalline or amorphous compound which is a substituted or unsubstituted folate or a reduced folate, or the natural or unnatural isomers thereof, of at least one organic base, as well as compositions and uses thereof. The compounds of the invention show a long lasting stability as well as a peculiarly high water-solubility.

Growing community of inventors

Desio, Italy

Davide Bianchi